伴t(8;21)/AML1-ETO阳性的儿童急性髓系白血病的临床特点及预后研究

摘要
图/表
参考文献(15)
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (1178 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要目的分析伴t(8;21)/AML1-ETO阳性的儿童急性髓系白血病（AML）的临床特点、生物学特征及预后。方法对伴t(8;21)/AML1-ETO阳性的55例AML患儿的临床资料进行回顾性分析，采用Kaplan-Meier 曲线评估患儿的无事件生存（EFS）率、无病生存(DFS)率和总生存(OS)率，COX回归模型评估预后因素。结果①55例伴t(8;21)/AML1-ETO阳性患儿中，4例放弃治疗，4例化疗1疗程后失访，47例患儿进行了双诱导方案化疗，1疗程、2疗程完全缓解率分别为71%和94%，复发10例（21%），47例患儿的5年EFS率、DFS率、OS率分别为（56.1±7.9）%、（59.8±8.1）%、（72.0±8.1）%。②多因素分析显示年龄是影响患儿预后的独立危险因素，年龄越大出现事故或死亡的风险性越大（P<0.05）。③缓解后继续巩固强化规范化疗的患儿（n=27）5年OS率明显高于不规范化疗的患儿（n=13）［（47.5±17.1）% vs （38.9±17.3）%，P<0.01］。结论伴t (8;21)/AML1-ETO阳性儿童AML是一类具有高度异质性的疾病，其治疗完全缓解率高，远期疗效好，年龄是决定远期疗效的重要因素之一，完全缓解后进行巩固强化规范化疗疗效较好。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	吴珺
	张乐萍
	陆爱东
	王彬
	程翼飞
	刘桂兰

关键词 ：髓系白血病, 预后, 生存分析, 儿童

Abstract：OBJECTIVE: To study the clinical and biological characteristics and prognosis of t(8;21)/AML1-ETO-positive childhood acute myeloid leukemia (AML). METHODS: The clinical data of 55 children who were diagnosed as t (8; 21)/AML1-ETO-positive AML were retrospectively studied. Event-free survival (EFS), disease-free survival (DFS), and overall survival (OS) rates were estimated by the Kaplan-Meier method. Prognostic factors were evaluated by COX regression analysis software. RESULTS: Of the 55 patients, 4 patients gave up treatment after the diagnosis was confirmed and 4 patients were lost to follow-up after the first chemotherapy course. The remaining 47 patients received a double-induction therapy. The total complete remission (CR) rate was 71% and 94% after the first and second chemotherapy course, respectively. The disease was relapsed in 10 patients (21%). The 5-year EFS, DFS and OS rates were (56.1±7.9)%, (59.8±8.1)%, and (72.0±8.1)%, respectively. Multivariate analysis showed that age was an independent risk factor for the long-term prognosis. The older children had a greater risk of experiencing an accident or death (P<0.05).The 5-year OS rate in 27 patients with regular consolidation chemotherapy was significantly higher than 13 patients with irregular chemotherapy after CR ［(47.5±17.1)% vs (38.9±17.3)%; P<0.01］. CONCLUSIONS: Childhood t(8;21)/AML1-ETO-positive AML is a highly heterogeneous disease, with a high CR rate and a good long-term prognosis. Age is one of the important factors affecting the long-term therapeutic effect. Regular consolidation chemotherapy applied after CR usually is helpful.

Key words： Myeloid leukemia Prognosis Survival analysis Child

PACS:

R733.71

引用本文:

吴珺,张乐萍,陆爱东等. 伴t(8;21)/AML1-ETO阳性的儿童急性髓系白血病的临床特点及预后研究[J]. 中国当代儿科杂志, 2011, 13(12): 931-935.

WU Jun,ZHANG Le-Ping,LU Ai-Dong et al. Clinical features and prognosis of t (8; 21)/AML1-ETO-positive childhood acute myeloid leukemia[J]. CJCP, 2011, 13(12): 931-935.

链接本文:

http://www.zgddek.com/CN/ 或 http://www.zgddek.com/CN/Y2011/V13/I12/931

	［1］Kwong YL, Ching LM, Liu HW, Lee CP, Pollock A, Chan LC. 8;21 translocation and multilineage involvement［J］. Am J Hematol, 1993, 43(3): 212-216.
	［2］Ravindranath Y, Chang M, Steuber CP, Becton D, Dahl G, Civin C, et al. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): A review of four consecutive childhood AML trials conducted between 1981 and 2000［J］. Leukemia, 2005, 19(12): 2101-2116.
	［3］Entz-Werle N, Suciu S, van der Werff ten Bosch J, Vilmer E, Bertrand Y, Benoit Y,et al. Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group report［J］. Leukemia, 2005, 19(12): 2072-2081.
	［4］殷慧君. 小儿急性白血病化疗治疗［M］. 北京:科学出版社,1996: 72-90.
	［5］张之南，沈悌．血液病诊断及疗效标准［M］．第2版．北京：科学出版社，1999：214-218.
	［6］Rowley JD. Identification of a translocation with quinacrine fluorescence in a patient with acute leukemia［J］. Ann Genet, 1973, 16(2):109-112.
	［7］陈玉梅, 赵要顺,邹尧，陈晓娟,张乃红,刘天峰, 等.伴t(8;21)／AML1-ETO的儿童急性髓系白血病的临床研究［J］. 中国小儿血液，2005，10(3)：99-102.
	［8］Hurwitz CA, Raimondi SC, Head D, Krance R, Mirro J Jr, Kalwinsky DK, et al. Distinctive immunophenotypic features of t(8;21) (q22;q22) acute myeloblastic leukemia in children［J］. Blood, 1992, 80（12）: 3182-3188.
	［9］何军,薛永权,何海龙,李建琴,宋晓翔,黄益萍, 等.t(8;21)儿童急性髓系白血病临床和生物学特征［J］. 中华医学遗传学杂志,2004,10(21):512-514.
	［10］von Neuhoff C, Reinhardt D, Sander A, Zimmermann M, Bradtke J, Betts DR, et al. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98［J］. J Clin Oncol, 2010, 28 (16): 2682-2689.
	［11］Abdel Rahman H, Farrag SA, El-Attar IA. AML1/ETO fusion gene in de novo pediatric acute myeloid leukemia: clinical significance and prognostic implications［J］. J Egypt Natl Canc Inst, 2007, 19(1):39-47.
	［12］Lie SO, Abrahamsson J, Clausen N, Forestier E, Hasle H, Hovi L, et al. Long-term results in children with AML: NOPHO-AML Study Group: report of three consecutive trials［J］. Leukemia, 2005, 19(12): 2090-2100.
	［13］Betts DR, Ammann RA, Hirt A, Hengartner H, Beck-Popovic M, Kuhne T, et al. The prognostic significance of cytogenetic aberrations in childhood acute myeloid leukaemia. A study of the Swiss Paediatric Oncology Group (SPOG)［J］. Eur J Haematol, 2007, 78(6): 468-476.
	［14］Woods WG, Neudorf S, Gold S, Sanders J, Buckley JD, Barnard DR, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission: a report from the Children Cancer Group［J］. Blood, 2001, 97(1): 56-62.
	［15］Alonzo TA, Wells RJ, Woods WG, Lange B, Gerbing RB, Buxton AB, et al. Postremission therapy for children with acute myeloid leukemia: the children's cancer group experience in the transplant era［J］. Leukemia, 2005, 19(6): 965-970.